within Pharmacolibrary.Drugs.ATC.A;

model A10BG02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.99,
    Cl             = 5.066666666666667e-05,
    adminDuration  = 600,
    adminMass      = 8 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0176,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005166666666666667,
    Tlag           = 24.0,            
    Vdp             = 0.0074,
    k12             = 4.69,
    k21             = 4.69
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10BG02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Rosiglitazone is an oral antidiabetic agent of the thiazolidinedione class. It functions as an insulin sensitizer by acting as a selective agonist at the peroxisome proliferator-activated receptor gamma (PPARγ). It is primarily used to treat type 2 diabetes mellitus to improve glycemic control. Due to concerns about cardiovascular safety, its use has been restricted in several regions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adults after single oral dose administration, both male and female subjects.</p><h4>References</h4><ol><li><p>Kosoglou, T, et al., &amp; Cutler, DL (2015). Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone. <i>Clinical pharmacology in drug development</i> 4(1) 56–62. DOI:<a href=\"https://doi.org/10.1002/cpdd.133\">10.1002/cpdd.133</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27128003/\">https://pubmed.ncbi.nlm.nih.gov/27128003</a></p></li><li><p>Al-Majed, A, et al., &amp; Al-Jenoobi, FI (2016). Pioglitazone. <i>Profiles of drug substances, excipients, and related methodology</i> 41 379–438. DOI:<a href=\"https://doi.org/10.1016/bs.podrm.2015.11.002\">10.1016/bs.podrm.2015.11.002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26940171/\">https://pubmed.ncbi.nlm.nih.gov/26940171</a></p></li><li><p>Wring, S, et al., &amp; Angulo, D (2018). Lack of Impact by SCY-078, a First-in-Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug-Drug Interactions. <i>Journal of clinical pharmacology</i> 58(10) 1305–1313. DOI:<a href=\"https://doi.org/10.1002/jcph.1146\">10.1002/jcph.1146</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29746713/\">https://pubmed.ncbi.nlm.nih.gov/29746713</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10BG02;
